Log In Get Started

News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • No major market-moving news published in the past hour.
  • No central bank statements or policy actions were reported in the past hour.
  • No significant economic data releases appeared in the past hour.
  • No major geopolitical or security developments were reported in the past hour.
  • No notable corporate earnings, M&A, or earnings guidance hit the wires in the past hour.
  • News flow was light, leaving markets without new headline catalysts for the hour.

Latest Articles

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting
Oct 1, 2026
Leila Farooq
Press Releases

Sight Sciences to Debut the OMNI Ultra® Surgical System, the Latest Technology Advancement from the Pioneers of Ab Interno Canaloplasty, at the 2026 American Academy of Ophthalmology (AAO) Annual Meeting

Sight Sciences has announced the commercial availability of the OMNI Ultra Surgical System, an advanced next-generation device expanding its pioneering ab interno canaloplasty platform. Showcased at the 2026 American Academy of Ophthalmology meeting, OMNI Ultra enhances procedural versatility and control to treat primary open-angle glaucoma by addr…

SGHT
Banc of California: Short Setup as Technicals and Fundamentals Diverge
Oct 1, 2026
Priya Menon
Trade Ideas

Banc of California: Short Setup as Technicals and Fundamentals Diverge

Banc of California (BANC) looks ripe for a mid-term pullback. The stock trades below its short- and medium-term moving averages, EPS is negative, and short interest has been climbing. Combine those technicals with an elevated enterprise value versus market cap and thin cash per share, and the risk/reward favors a tactical short into the $15 area. T…

BANC
Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base
Oct 1, 2026
Ajmal Hussain
Press Releases

Origin Agritech Strengthens Liquidity by Selling Its Xinjiang Seed Subsidiary and Leasing Back the Production Base

Origin Agritech Limited announced the sale of its 70.5% equity interest in its Xinjiang Originbo seed production base to Hunan Xindaxin Limited for approximately US$15 million. Concurrently, a five-year lease-back agreement ensures operational continuity at the production facility, preserving seed supply stability. The proceeds will be deployed to …

SEED
Anfield Energy Receives Positive Colorado DRMS Decision Completing State Review of JD-8 Uranium-Vanadium Mine
Oct 1, 2026
Leila Farooq
Press Releases

Anfield Energy Receives Positive Colorado DRMS Decision Completing State Review of JD-8 Uranium-Vanadium Mine

Anfield Energy received approval from the Colorado Division of Reclamation, Mining and Safety on the reclamation permit application for its JD-8 uranium and vanadium mine, a key asset in Anfield's Monogram Mesa Mine Complex. The decision clears state-level permitting, with federal approvals underway, targeting a restart of production by mid-2027. T…

AEC
USA Rare Earth Completes CEO Transition
Oct 1, 2026
Leila Farooq
Press Releases

USA Rare Earth Completes CEO Transition

USA Rare Earth, a Nasdaq-listed rare earth and critical minerals company, has completed its CEO succession with Thras Moraitis stepping into the role. Moraitis aims to integrate the company's diverse operations across mining, processing, and magnet manufacturing in the US, Brazil, and UK. The company is structured into three business units to enhan…

USAR
Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer
Oct 1, 2026
Priya Menon
Press Releases

Roswell Park, Generate Biomedicines Launch Exclusive Clinical Trial of ‘Armored’ CAR T Therapy for Ovarian Cancer

Generate Biomedicines and Roswell Park Comprehensive Cancer Center have initiated a Phase 1 clinical trial for GB-5267, an investigational AI-designed IL-18 armored CAR T-cell therapy aimed at treating platinum-resistant ovarian cancer by targeting the MUC16 antigen. The approach focuses on overcoming solid tumor microenvironment challenges without…

GENB
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Oct 1, 2026
Sofia Navarro
Press Releases

Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors

Kyntra Bio announces the appointment of Andrew E. Singer, MBA, a seasoned biotechnology finance and strategy executive, to its Board of Directors and Audit Committee. The move aims to leverage Mr. Singer's extensive expertise to advance the company's rare disease and oncology pipeline and support strategic priorities. Concurrently, long-serving boa…

KYNB
Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk
Oct 1, 2026
Jordan Park
Press Releases

Monte Rosa Therapeutics Announces Positive Results for MRT-8102 in GFORCE-1 Phase 1 Study Showing Normalization of Key Pathogenic Drivers of ASCVD in Subjects with Elevated CVD Risk

Monte Rosa Therapeutics announced positive results from its GFORCE-1 Phase 1 study of MRT-8102, a NEK7-directed molecular glue degrader targeting inflammatory pathways linked to atherosclerotic cardiovascular disease (ASCVD). In obese subjects with elevated cardiovascular risk, MRT-8102 demonstrated robust NEK7 degradation and significant reduction…

GLUE
What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?
Oct 1, 2026
Ajmal Hussain
Press Releases

What Are the 5 Signs of Poor Metabolic Health Adults May Overlook?

Medifast's Trilivy metabolic health system identifies five often overlooked signs of poor metabolic health and offers a structured framework, incorporating its MetaVantage Reset Formula and coaching support, to improve metabolic outcomes. A clinical trial showed 14% reduction in visceral fat and 98% lean mass retention over 16 weeks, supporting the…

MED
Fervo Energy Declares Commercial Operation at Cape Station Ahead of Schedule, Leading the Race for Next-Generation Geothermal Energy
Oct 1, 2026
Sofia Navarro
Press Releases

Fervo Energy Declares Commercial Operation at Cape Station Ahead of Schedule, Leading the Race for Next-Generation Geothermal Energy

Fervo Energy announced that its first GeoBlock at Cape Station in Utah achieved commercial operation ahead of schedule, generating 33 MW of net power and starting revenue under its power purchase agreement. This milestone establishes Fervo's leadership in enhanced geothermal systems (EGS) and signals the viability of reliable, carbon-free power pro…

FRVO
Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development
Oct 1, 2026
Priya Menon
Press Releases

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

Shattuck Labs, a biotech company focused on inflammatory and immune-mediated diseases, announced plans to start a Phase 2 clinical trial in 2026 to evaluate its drug candidate SL-325 for moderate to severe hidradenitis suppurativa (HS). The company also appointed Dr. Shoba Ravichandran as Senior Vice President of Clinical Development to lead this p…

STTK
Imperial Brands: A Measured Long — Waiting For the Low-30s Entry
Oct 1, 2026
Ajmal Hussain
Trade Ideas

Imperial Brands: A Measured Long — Waiting For the Low-30s Entry

Imperial Brands (IMBBY) is trading near its 52-week low with a 6.7% yield, single-digit-ish valuation (PE ~11.3) and oversold technicals (RSI ~31). That combination offers a tactical long entry for a mid-term swing trade if price stabilizes near $32. This idea lays out a clear entry, stop and target with catalysts and risks to watch.

IMBBY
Fujifilm Re-rated: Sell-Off, Spin-Off and a Clear Path to Re-Rating
Oct 1, 2026
Caleb Monroe
Trade Ideas

Fujifilm Re-rated: Sell-Off, Spin-Off and a Clear Path to Re-Rating

FUJIY is a buy here. Management's decision to sell a non-core business and spin off another creates a near-term rerating opportunity: the stock trades at $10.55 with a $26.0B market cap, a modest 15x PE and 1.05x PB. With improving healthcare/biotech exposure, attractive semiconductor materials tailwinds, and technicals showing constructive momentu…

FUJIY